Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > mRNA vaccine company Phase 2 trial fails on wrong biomarker

<< Previous

Bullboard Posts

Next >>

Comment by itntdfon May 03, 2024 10:27am

122 Views

Post# 36021532

RE:RE:mRNA vaccine company Phase 2 trial fails on wrong biomarker

this is why oncy is in front of, not behind, the eight ball. oncy has already ramped up its manufacturing capacity:

That’s contingent on substantially enrolling the phase 3 melanoma study, which would serve as the confirmatory trial, and building up manufacturing capacity at a Marlborough, Massachusetts site.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities